Contribute Try STAT+ Today

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and keep in mind that there are only a few more days until the weekend arrives. So keep plugging away, although do remember to keep a healthy distance from the rest of the world. After all, what are the alternatives? Meanwhile, here is the latest menu of tidbits to help you on your way. Have a smashing and please do stay in touch.

The push to increase testing in the U.S. for the novel coronavirus that causes Covid-19 has hit a new stumbling block: shortages of key chemicals needed to start up and run the tests, STAT explains. In particular, one key product, made by the diagnostics testing giant Qiagen (QGEN), is in dwindling supply. The chemical is used to isolate the virus’ genetic material, or RNA, so that it can be tested. A Qiagen spokesperson acknowledged that “extraordinary” demand was limiting the company’s ability to supply some products.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.